Claritev (CTEV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
Definitive additional proxy materials filed regarding upcoming shareholder meeting.
No filing fee required for this submission, as indicated in the materials.
Voting matters and shareholder proposals
Materials relate to solicitation of proxies for voting at the annual meeting.
Shareholder rights and capital structure
Proxy materials filed to inform shareholders of their rights and voting procedures.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Claritev
- 2024 net loss surged on a $1.49B impairment as transformation and rebranding drive long-term optimism.CTEV
Q4 20249 Jul 2026 - Q1 2025 revenue was $231.3M, net loss narrowed, and transformation advanced.CTEVQ1 20259 Jul 2026
- Six new market segments, tech innovation, and a $200M pipeline drive growth into 2026.CTEVBofA Securities Leveraged Finance Conference 20258 Jul 2026
- Transformation and innovation drive growth, profitability, and expanded market reach.CTEV44th Annual J.P. Morgan Healthcare Conference8 Jul 2026
- Record bookings, tech investment, and strong client ties drive ambitious 2030 growth targets.CTEVBank of America Global Healthcare Conference 202614 May 2026
- Q1 2026 revenue grew 5.8% to $244.7M, with margin gains but continued net losses.CTEVQ1 20267 May 2026
- All proposals, including director elections and plan amendments, were approved without contest.CTEVAGM 202629 Apr 2026
- 2026 guidance targets $980M–$1B revenue, 61–62% EBITDA margin, and AI-driven growth.CTEVInvestor Day 202629 Apr 2026
- Board recommends all proxy proposals amid strong 2025 results and governance enhancements.CTEVProxy filing20 Mar 2026